Skip to main content
SpringerLink
Log in

Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm

BTX improves dry eye in patients with BEB

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Background/aims

To evaluate the effects of botulinum toxin type A (BTX-A) treatment in patients with benign essential blepharospasm (BEB) by monitoring the ocular surface and ocular higher-order aberrations (HOAs) before and after treatment.

Methods

The present study reports a prospective case series of 38 patients (76 eyes, 11 men and 27 women; mean age 66.8 ± 9.8 years) with BEB who underwent BTX-A treatment at Kokura Memorial Hospital between 2013 and 2014. Patients were evaluated for ophthalmoscopic findings, Schirmer I test, tear film break-up time (t-BUT), HOAs, fluctuation index (FI), stability index (SI) using a wavefront aberrometer, 15 subjective symptoms using the Dry Eye-Related Quality of Life Score (DEQS), and complications before and after the treatment.

Results

After BTX-A treatment, the Schirmer I test score improved significantly from 5.9 ± 5.4 to 8.7 ± 6.1 mm and t-BUT recovered from 5.2 ± 1.7 to 7.3 ± 1.7 s. HOAs were classified into four patterns: stable (60.5 %), small fluctuation (14.5 %), sawtooth (17.1 %), and reverse sawtooth (7.9 %), and they significantly reduced after the treatment. Only FI (not SI) showed a marked reduction, and the DEQS significantly improved from 44.7 ± 21.6 to 37.6 ± 21.0 after the treatment (p < 0.05). There were no complications during the observations.

Conclusion

BTX-A is a treatment with a high potential to improve ocular surface disorders induced by BEB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–d
Fig. 2

Similar content being viewed by others

References

  1. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthalmic Plast Reconstr Surg. 1998;14:305–17.

    Article  CAS  Google Scholar 

  2. Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs. 2004;64:237–44.

    Article  PubMed  Google Scholar 

  3. Marsden CD. Blepharospasm–oromandibular dystonia syndrome (Brueghel’s syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry. 1976;39:1204–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kerrison JB, Lancaster JL, Zamarripa FE, Richardson LA, Morrison JC, Holck DE, et al. Positron emission tomography scanning in essential blepharospasm. Am J Ophthalmol. 2003;136:846–52.

    Article  PubMed  Google Scholar 

  5. Suzuki Y, Mizoguchi S, Kiyosawa M, Mochizuki M, Ishiwata K, Wakakura M, et al. Glucose hypermetabolism in the thalamus of patients with essential blepharospasm. J Neurol. 2007;254:890–6.

    Article  PubMed  Google Scholar 

  6. Emoto H, Suzuki Y, Wakakura M, Horie C, Kiyosawa M, Mochizuki M, et al. Photophobia in essential blepharospasm—a positron emission tomographic study. Mov Disord Off J Mov Disord Soc. 2010;25:433–9. doi:10.1002/mds.22916.

  7. Etgen T, Muhlau M, Gaser C, Sander D. Bilateral grey-matter increase in the putamen in primary blepharospasm. J Neurol Neurosurg Psychiatry. 2006;77:1017–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA. 1982;248:3160–4.

    Article  CAS  PubMed  Google Scholar 

  9. Obermann M, Yaldizli O, De Greiff A, Lachenmayer ML, Buhl AR, Tumczak F, et al. Morphometric changes of sensorimotor structures in focal dystonia. Mov Disord. 2007;22:1117–23.

    Article  PubMed  Google Scholar 

  10. Elston JS, Marsden CD, Grandas F, Quinn NP. The significance of ophthalmological symptoms in idiopathic blepharospasm. Eye. 1988;2(Pt 4):435–9.

    Article  PubMed  Google Scholar 

  11. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tsubota K, Fujihara T, Kaido M, Mori A, Mimura M, Kato M. Dry eye and Meige’s syndrome. Br J Ophthal. 1997;81:439–42.

    Article  CAS  Google Scholar 

  13. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol. 1985;99:542–6.

    Article  CAS  PubMed  Google Scholar 

  14. Price J, O’Day J. A comparative study of tear secretion in blepharospasm and hemifacial spasm patients treated with botulinum toxin. J Clin Neuroophthalmol. 1993;13:67–71.

  15. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjogren’s syndrome: a preliminary report. J Rheumatol. 1997;24:1842–3.

    CAS  PubMed  Google Scholar 

  16. Park DI, Shin HM, Lee SY, Lew H. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm. Acta Ophthalmol. 2013;91:e108–12. doi:10.1111/aos.12002.

    Article  PubMed  Google Scholar 

  17. Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014;157(591–7):e1–2. doi:10.1016/j.ajo.2013.11.014.

    Google Scholar 

  18. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–73. doi:10.1002/mds.25475.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29:579–89. doi:10.1007/s12325-012-0033-9.

    Article  CAS  PubMed  Google Scholar 

  20. Wakakura M, Tsubouchi T, Inouye J. Etizolam and benzodiazepine induced blepharospasm. J Neurol Neurosurg Psychiatry. 2004;75:506–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sakane Y, Yamaguchi M, Yokoi N, Uchino M, Dogru M, Oishi T, et al. Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol. 2013;131:1331–8. doi:10.1001/jamaophthalmol.2013.4503.

  22. Koh S, Maeda N, Hori Y, Inoue T, Watanabe H, Hirohara Y, et al. Effects of suppression of blinking on quality of vision in borderline cases of evaporative dry eye. Cornea. 2008;27:275–8. doi:10.1097/ICO.0b013e31815be9c8.

    Article  PubMed  Google Scholar 

  23. Koh S, Maeda N, Hirohara Y, Mihashi T, Ninomiya S, Bessho K, Watanabe H, Fujikado T, Tano Y. Serial measurements of higher-order aberrations after blinking in normal subjects. Invest Ophthalmol Vis Sci. 2006;47:3318–24.

    Article  PubMed  Google Scholar 

  24. Koh S, Maeda N, Hirohara Y, Mihashi T, Bessho K, Hori Y, Inoue T, Watanabe H, Fujikado T, Tano Y. Serial measurements of higher-order aberrations after blinking in patients with dry eye. Invest Ophthalmol Vis Sci. 2008;49:133–8. doi:10.1167/iovs.07-0762.

    Article  PubMed  Google Scholar 

  25. Koh S, Maeda N, Ninomiya S, Watanabe H, Fujikado T, Tano Y, et al. Paradoxical increase of visual impairment with punctal occlusion in a patient with mild dry eye. J Cataract Refract Surg. 2006;32:689–91.

    Article  PubMed  Google Scholar 

  26. Victoria AC, Pino A. Botulinum toxin type a and its uses in dry eye disease. Plast Reconstr Surg. 2012;130:209e–10e. doi:10.1097/PRS.0b013e31825500ba.

    Article  CAS  PubMed  Google Scholar 

  27. Yokoi N, Georgiev GA. Tear-film-oriented diagnosis and therapy for dry eye. In: Yokoi N, editor. Dry eye syndrome: basic and clinical perspectives. London: Future Medicine Ltd.; 2013. p. 96–108.

  28. Yabiku MM, Sartori Jde F, Sarraff EP, Osaki TH, Hossaka SK, Pereira CI, et al. Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin. Arq Bras Oftalmol. 2011;74:414–6 (in Portuguese).

  29. Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32:1219–23. doi:10.1097/ICO.0b013e318294f97e.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. David Eve (University of South Florida, Tampa, FL, USA) for his critical advice, comments, and for editing the English of the manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan

    Yoshihiko Isshiki, Hiroto Ishikawa & Osamu Mimura

  2. Department of Ophthalmology, Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan

    Yoshihiko Isshiki

Authors
  1. Yoshihiko Isshiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroto Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osamu Mimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiko Isshiki.

Ethics declarations

Conflicts of interest

Y. Isshiki, none; H. Ishikawa, none; O. Mimura, none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Isshiki, Y., Ishikawa, H. & Mimura, O. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm. Jpn J Ophthalmol 60, 486–491 (2016). https://doi.org/10.1007/s10384-016-0469-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-016-0469-6

Keywords

Search

Navigation